Anti-fibrotic effect of tocotrienols for bladder dysfunction due to partial bladder outlet obstruction

Area of Science:

• Urology
• Pharmacology
• Molecular Biology

Background:

• Partial bladder outlet obstruction (PBOO) can lead to significant bladder pathology.
• The hypoxia-inducible factor (HIF) pathway is implicated in PBOO-induced changes.
• Tocotrienols are investigated for their potential to modulate the HIF pathway.

Purpose of the Study:

• To evaluate the therapeutic potential of tocotrienols in a mouse model of PBOO.
• To determine if tocotrienols can mitigate PBOO-induced bladder dysfunction and pathology.
• To assess the role of the HIF pathway in tocotrienol's effects on PBOO.

Main Methods:

• Surgical creation of PBOO in juvenile male mice, with sham-operated controls.
• Oral administration of tocotrienols or vehicle (soybean oil) for 13 days post-surgery.
• Assessment of bladder function, contractility, histology, and gene expression, including HIF target genes.

Main Results:

• PBOO increased urinary frequency and bladder fibrosis, indicated by increased collagen.
• Tocotrienol treatment significantly reduced bladder fibrosis compared to vehicle treatment.
• Tocotrienols suppressed the upregulation of HIF target genes observed in PBOO-induced bladders.

Conclusions:

• Tocotrienols demonstrate a protective effect against PBOO-induced bladder fibrosis.
• The antifibrotic effects of tocotrienols are associated with the suppression of the HIF pathway.
• Tocotrienol treatment may be a viable strategy to manage PBOO-related bladder pathology.